Vis enkel innførsel

dc.contributor.authorEnoksen, Inger Therese T.
dc.contributor.authorSvistounov, Dmitri
dc.contributor.authorNorvik, Jon Viljar
dc.contributor.authorStefansson, Vidar Tor Nyborg
dc.contributor.authorSolbu, Marit Dahl
dc.contributor.authorEriksen, Bjørn Odvar
dc.contributor.authorMelsom, Toralf
dc.date.accessioned2022-01-31T08:15:49Z
dc.date.available2022-01-31T08:15:49Z
dc.date.issued2021-08-26
dc.description.abstractBackground. Age-related reduction of glomerular filtration rate (GFR) is a major contributor to the global chronic kidney disease (CKD) epidemic. We investigated whether baseline serum levels of the pro-fibrotic matrix metalloproteinase 2 (MMP2), MMP7 and their inhibitor, tissue inhibitor of metalloproteinase 1 (TIMP1), which mediates fibrosis development in aging animals, were associated with GFR decline in a general non-diabetic population.<p> <p>Methods. In the Renal Iohexol Clearance Survey, we measured GFR using iohexol clearance in 1627 subjects aged 50–64 years without self-reported diabetes, kidney or cardiovascular disease.After a median of 5.6 years, 1324 had follow-up GFR measurements. Using linear mixed models and logistic regression analyses, we evaluated the association of MMP7, MMP2 and TIMP1 with the mean GFR decline rate, risk of accelerated GFR decline (defined as subjects with the 10% steepest GFR slopes: 1.8 mL/min/1.73 m<sup>2</sup> /year) and incident CKD [GFR<60 mL/ min/1.73 m<sup>2</sup> and/or urinary albumin to creatinine ratio (ACR) 3.0 mg/mmol].<p> <p>Results. Higher MMP7 levels (per standard deviation increase of MMP7) were associated with steeper GFR decline rates [0.23 mL/min/1.73 m<sup>2</sup> /year (9<5% confidence interval 0.34 to 0.12)] and increased risk of accelerated GFR decline and incident CKD [odds ratios 1.58 (1.30–1.93) and 1.45 (1.05–2.01), respectively, in a model adjusted for age, sex, baseline GFR, ACR and cardiovascular risk factors]. MMP2 and TIMP1 showed no association with GFR decline or incident CKD. Conclusions. The pro-fibrotic biomarker MMP7, but not MMP2 or TIMP1, is associated with increased risk of accelerated GFR decline and incident CKD in middle-aged persons from the general population.en_US
dc.identifier.citationEnoksen, Svistounov, Norvik, Stefansson, Solbu, Eriksen, Melsom. Serum Matrix Metalloproteinase 7 and accelerated glomerular filtration rate decline in a general non-diabetic population. Nephrology, Dialysis and Transplantation. 2021en_US
dc.identifier.cristinIDFRIDAID 1971651
dc.identifier.doi10.1093/ndt/gfab251
dc.identifier.issn0931-0509
dc.identifier.issn1460-2385
dc.identifier.urihttps://hdl.handle.net/10037/23837
dc.language.isoengen_US
dc.publisherOxford University Pressen_US
dc.relation.ispartofEnoksen, I.T.T. (2023). Novel serum biomarkers and their association with measured and estimated GFR decline in the general population. (Doctoral thesis). <a href=https://hdl.handle.net/10037/30560>https://hdl.handle.net/10037/30560</a>
dc.relation.journalNephrology, Dialysis and Transplantation
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2021 The Author(s)en_US
dc.titleSerum Matrix Metalloproteinase 7 and accelerated glomerular filtration rate decline in a general non-diabetic populationen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel